Inflammatory markers in age-related maculopathy: Cross-sectional analysis from the Muenster Aging and Retina Study

Archives of Ophthalmology

Volumn 123, Issue 11, 2005, Pages 1501-1506

  Dasch, Burkhard ^a   Fuhs, Andrea ^a   Behrens, Thomas ^a   Meister, Astrid ^b   Wellmann, Juergen ^a   Fobker, Manfred ^a   Pauleikhoff, Daniel ^b   Hense, Hans Werner ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PHOTOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; GERMANY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETINA; RISK FACTORS;

EID: 27744450912     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.123.11.1501     Document Type: Article

References (45)

1. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109:1767-1779.
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam Study. Arch Ophthalmol. 2003;121:519-526.
3. Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109:1092-1097.
4. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP Report 2. Arch Ophthalmol. 2001;119:198-207.
5. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol. 2003;136:407-418.
6. Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? results of a systematic review. Br J Ophthalmol. 2004;88:212-217.
7. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
8. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and agerelated macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
9. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.
10. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:11830-11835.
11. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
12. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
13. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
15. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-2485.
16. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2004;11:9-17.
17. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004;62:499-506.
18. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697-704.
19. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110:1273-1280.
20. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44:3771-3777.
21. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999;6:125-143.
22. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 1998;116:583-587.
23. Eye Disease Case-Control Study Group. Risk factors for neovascular agerelated macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
24. Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the Cardiovascular Health Study. Ophthalmology. 2003;110:25-33.
25. Klein R. Epidemiology. In: Berger JW, Fine SL, Maguire MG, eds. Age-Related Macular Degeneration. St Louis, Mo: Mosby-Year Book Inc; 1999:31-55.
26. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol. 2003;121:674-678.
27. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704-710.
28. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-1058.
29. Bird AC, Bressler NM, Bressler SB, et al; International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995;39:367-374.
30. Clauss A. Rapid physiological coagulation method in determination of fibrinogen [in German]. Acta Haematol. 1957;17:237-246.
31. Katz J, Zeger S, Liang KY. Appropriate statistical methods to account for similarities in binary outcomes between fellow eyes. Invest Ophthalmol Vis Sci. 1994;35:2461-2465.
32. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122:598-614.
33. Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990;4:613-621.
34. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223:69-76.
35. Dastgheib K, Green WR. Granulomatous reaction to Bruch's membrane in agerelated macular degeneration. Arch Ophthalmol. 1994;112:813-818.
36. Penfold PL, Liew SC, Madigan MC, Provis JM. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:2125-2133.
37. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:14682-14687.
38. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
39. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-449.
40. Friedman E. The role of the atherosclerotic process in the pathogenesis of agerelated macular degeneration. Am J Ophthalmol. 2000;130:658-663.
41. Wang JJ, Mitchell P, Smith W, Gillies M, Billson F. Systemic use of antiinflammatory medications and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2003;10:37-48.
42. Bergmann KE, Mensink GB. Anthropometric data and obesity [in German]. Gesundheitswesen. 1999;61(spec No.):S115-S120.
43. Thamm M. Blood pressure in Germany: current status and trends [in German]. Gesundheitswesen. 1999;61(spec No.):S90-S93.
44. Junge B, Nagel M. Smoking behavior in Germany [in German]. Gesundheitswesen. 1999;61(spec No.):S121-S125.
45. Imhof A, Frohlich M, Loewel H, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem. 2003;49:669-672.